Phenylketonuria Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)
Description
The phenylketonuria treatment market was valued at USD 905.71 Million in 2024 driven by the rising incidence of phenylketonuria and advancements in treatment options across the 8 major markets. It is expected to grow at a CAGR of 8.10% during the forecast period 2025-2034 and attain a market value of USD 1973.54 Million by 2034.
Phenylketonuria Treatment Market Overview
Phenylketonuria (PKU) is an uncommon genetic condition resulting from an alteration in the PAH gene that results in a deficiency of the phenylalanine hydroxylase enzyme. This enzyme is crucial for metabolizing phenylalanine, a necessary amino acid for proper bodily function. If lacking, phenylalanine builds up in the bloodstream and brain, leading to dangerous levels that may lead to significant delays in development and cognitive impairments. If not addressed, phenylketonuria can result in permanent brain damage and cognitive deficiencies.
Individuals with phenylketonuria need to follow a low-protein diet and regularly check their phenylalanine levels throughout their lives to stay healthy. It is managed by limiting phenylalanine consumption with a low-protein diet and specific medical products. Prompt diagnosis and treatment are essential to prevent delays in development. Routine monitoring of phenylalanine levels in the blood is crucial for successful therapy.
Other treatment alternatives consist of medications such as sapropterin dihydrochloride and enzyme replacement treatments like pegvaliase. Research in gene therapy strives to fix the genetic abnormality at its root cause. Phenylketonuria is detected in newborn screening programs but following a low-protein diet may present difficulties. Low-phenylalanine food items enhance quality of life but can be costly and challenging to locate. Getting psychological and social support from healthcare providers and phenylketonuria advocacy groups is essential in dealing with the complexities of the condition.
Phenylketonuria Treatment Market Growth Drivers
Growing Prevalence of Phenylketonuria Spurs Market Growth
Phenylketonuria occurs due to a lack of the enzyme phenylalanine hydroxylase (PAH), resulting in an accumulation of phenylalanine in the bloodstream and the development of serious neurological issues if not addressed. National PKU Alliance reports that 1 in 25,000 individuals in the United States are living with phenylketonuria. This implies that around 13,500 people with phenylketonuria are currently residing in the United States as of 2024. The increasing number of confirmed cases is fueling the need for continuous management options such as specific diets and treatments, which is expected to boost the market growth in the coming years.
Advancements in Treatment Options Likely to Augment Phenylketonuria Treatment Market Demand
The market for specialized medical foods and therapies for phenylketonuria patients is expanding, with new pharmaceutical choices such as sapropterin dihydrochloride and pegvaliase providing options beyond conventional dietary limitations. In Oct 2024, PTC Therapeutics announced the FDA acceptance for filing of a New Drug Application (NDA) for Sepiapterin to treat pediatric and adult phenylketonuria patients. Enzyme replacement therapies and new gene therapy methods are broadening treatment options, appealing to patients seeking better ways to manage their condition. Advancements in research are driving innovation in the treatment market for phenylketonuria, leading to an increase in demand for non-dietary treatments.
Phenylketonuria Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Gene Therapy Advancements are Expected to Impact Market Landscape
Gene therapy is offering hope for the treatment of phenylketonuria (PKU) by fixing the genetic mutation in the PAH gene to bring back the enzyme phenylalanine hydroxylase function. Research has indicated progress in transferring functional PAH gene copies to the liver, which could offer a lasting or permanent solution and remove the necessity for lifelong care. This marks substantial progress in phenylketonuria therapy, providing a single treatment option that has the potential to enhance patient results significantly.
Expansion of Newborn Screening Programs Poised to Boost Phenylketonuria Treatment Market Size
The expansion of newborn screening programs is facilitating the early detection of phenylketonuria cases, leading to an increased demand for treatments. Timely identification via these initiatives helps avoid serious issues, underscoring the significance of thorough infant screening guidelines in enhancing prospects for individuals with PKU and stimulating market expansion.
Increasing Collaborations and Partnerships Set to Elevate the Phenylketonuria Treatment Market Value
The rise in collaborations and partnerships in the PKU treatment sector is spurring innovation and broadening the availability of specialized medical foods and medications. Pharmaceutical companies, research institutions, and healthcare providers are collaborating to speed up research on new treatments, such as gene therapy and enzyme replacement. These collaborations are also aiding companies in understanding patient requirements and influencing the development of future therapies.
Rising Investments in Research and Development to Support Market Growth
Increased funding in R&D is driving progress in pharmacological therapies for phenylketonuria, specifically focusing on gene-editing tools and enhanced medical nutrition. The market for treating phenylketonuria is experiencing growth opportunities due to government funding and grants supporting rare disease research.
Phenylketonuria Treatment Market Segmentation
The EMR’s report titled “Phenylketonuria Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
Market Segmentation Based on the Drugs to Witness Growth
The market is segmented into Kuvan, CNSA-001, SYNB1618, Palynziq, and other drugs. Kuvan is frequently prescribed for patients with mild to moderate phenylketonuria as it boosts the activity of the PAH enzyme, providing a non-invasive treatment option for the condition. It is the first oral medication for phenylketonuria that was approved by the FDA and proven to lower phenylalanine levels in patients with certain enzyme functions. Kuvan is frequently combined with dietary control, making it a crucial part of treatment for numerous phenylketonuria patients because of its established efficacy and extensive presence in the market.
Distribution Channel Segment Represents Substantial Market Share
Hospitals and clinics, retail pharmacies, and others together make up the distribution channel segment of the market. Retail pharmacies provide convenient access to specialized dietary items, medications such as Kuvan and Palynziq, low-protein foods, and amino acid supplements. Patients prefer using retail pharmacies to refill medications and supplies to avoid making numerous trips to the hospital.
Phenylketonuria Treatment Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market due to its advanced healthcare system, widespread newborn screening, and strong research and development. Mandatory newborn screening across all states enables early identification and prompt intervention, while market growth is fueled by the availability of innovative therapies. Further, extensive support for phenylketonuria patients is also offered by the United States, which is anticipated to elevate the market value in the forecast period.
EU-4 and the United Kingdom are also poised to have a significant market share supported by robust healthcare systems and government screening initiatives to promote early intervention for genetic conditions. In Oct 2023, POA Pharma launched PKU Easy Microtabs Plus in Germany and the Nordic region. These microtabs are for individuals with phenylketonuria (PKU), marking POA Pharma's entry into the inborn metabolic disease market. The product is a phenylalanine-free protein substitute in micro tablet form, enriched with vitamins and minerals, eliminating the need for separate supplements.Europe's regulations support new phenylketonuria treatments, making them more accessible to patients.
The market in the Japan and India region is rapidly expanding. Japan's extensive screening program and state-of-the-art medical facilities are promoting the expansion of treatment options. On the other side, India's healthcare system is still in the process of development, with the government making substantial efforts for advancements in phenylketonuria diagnosis and treatment.
Leading Players in the Phenylketonuria Treatment Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., headquartered in California, creates groundbreaking medications for rare genetic disorders and illnesses. Their product portfolio includes PALYNZIQ ® (pegvaliase), which is utilized in adults with phenylketonuria (PKU) when alternative approaches such as dietary management prove to be ineffective.
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Homology Medicines, Inc.
Homology Medicines, Inc. is a genetic medicines company focused on rare diseases, aiming to address the root cause of the illness. In July 2023, they shared positive early clinical results for gene editing treatment HMI-103 in adults with classical phenylketonuria (PKU), a severe form of the disease.
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical needs.
Other players in the market are Synology Inc., SOM Innovation Biotech S.A, ERYTECH Pharma S.A, Codexis Inc., Retrophin, Inc., and Abbott Laboratories.
Key Questions Answered in the Phenylketonuria Treatment Market Report
Phenylketonuria Treatment Market Overview
Phenylketonuria (PKU) is an uncommon genetic condition resulting from an alteration in the PAH gene that results in a deficiency of the phenylalanine hydroxylase enzyme. This enzyme is crucial for metabolizing phenylalanine, a necessary amino acid for proper bodily function. If lacking, phenylalanine builds up in the bloodstream and brain, leading to dangerous levels that may lead to significant delays in development and cognitive impairments. If not addressed, phenylketonuria can result in permanent brain damage and cognitive deficiencies.
Individuals with phenylketonuria need to follow a low-protein diet and regularly check their phenylalanine levels throughout their lives to stay healthy. It is managed by limiting phenylalanine consumption with a low-protein diet and specific medical products. Prompt diagnosis and treatment are essential to prevent delays in development. Routine monitoring of phenylalanine levels in the blood is crucial for successful therapy.
Other treatment alternatives consist of medications such as sapropterin dihydrochloride and enzyme replacement treatments like pegvaliase. Research in gene therapy strives to fix the genetic abnormality at its root cause. Phenylketonuria is detected in newborn screening programs but following a low-protein diet may present difficulties. Low-phenylalanine food items enhance quality of life but can be costly and challenging to locate. Getting psychological and social support from healthcare providers and phenylketonuria advocacy groups is essential in dealing with the complexities of the condition.
Phenylketonuria Treatment Market Growth Drivers
Growing Prevalence of Phenylketonuria Spurs Market Growth
Phenylketonuria occurs due to a lack of the enzyme phenylalanine hydroxylase (PAH), resulting in an accumulation of phenylalanine in the bloodstream and the development of serious neurological issues if not addressed. National PKU Alliance reports that 1 in 25,000 individuals in the United States are living with phenylketonuria. This implies that around 13,500 people with phenylketonuria are currently residing in the United States as of 2024. The increasing number of confirmed cases is fueling the need for continuous management options such as specific diets and treatments, which is expected to boost the market growth in the coming years.
Advancements in Treatment Options Likely to Augment Phenylketonuria Treatment Market Demand
The market for specialized medical foods and therapies for phenylketonuria patients is expanding, with new pharmaceutical choices such as sapropterin dihydrochloride and pegvaliase providing options beyond conventional dietary limitations. In Oct 2024, PTC Therapeutics announced the FDA acceptance for filing of a New Drug Application (NDA) for Sepiapterin to treat pediatric and adult phenylketonuria patients. Enzyme replacement therapies and new gene therapy methods are broadening treatment options, appealing to patients seeking better ways to manage their condition. Advancements in research are driving innovation in the treatment market for phenylketonuria, leading to an increase in demand for non-dietary treatments.
Phenylketonuria Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Gene Therapy Advancements are Expected to Impact Market Landscape
Gene therapy is offering hope for the treatment of phenylketonuria (PKU) by fixing the genetic mutation in the PAH gene to bring back the enzyme phenylalanine hydroxylase function. Research has indicated progress in transferring functional PAH gene copies to the liver, which could offer a lasting or permanent solution and remove the necessity for lifelong care. This marks substantial progress in phenylketonuria therapy, providing a single treatment option that has the potential to enhance patient results significantly.
Expansion of Newborn Screening Programs Poised to Boost Phenylketonuria Treatment Market Size
The expansion of newborn screening programs is facilitating the early detection of phenylketonuria cases, leading to an increased demand for treatments. Timely identification via these initiatives helps avoid serious issues, underscoring the significance of thorough infant screening guidelines in enhancing prospects for individuals with PKU and stimulating market expansion.
Increasing Collaborations and Partnerships Set to Elevate the Phenylketonuria Treatment Market Value
The rise in collaborations and partnerships in the PKU treatment sector is spurring innovation and broadening the availability of specialized medical foods and medications. Pharmaceutical companies, research institutions, and healthcare providers are collaborating to speed up research on new treatments, such as gene therapy and enzyme replacement. These collaborations are also aiding companies in understanding patient requirements and influencing the development of future therapies.
Rising Investments in Research and Development to Support Market Growth
Increased funding in R&D is driving progress in pharmacological therapies for phenylketonuria, specifically focusing on gene-editing tools and enhanced medical nutrition. The market for treating phenylketonuria is experiencing growth opportunities due to government funding and grants supporting rare disease research.
Phenylketonuria Treatment Market Segmentation
The EMR’s report titled “Phenylketonuria Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
- Kuvan
- CNSA-001
- SYNB1618
- Palynziq
- Others
- Oral
- Parenteral
- Hospital and Clinics
- Retail Pharmacies
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on the Drugs to Witness Growth
The market is segmented into Kuvan, CNSA-001, SYNB1618, Palynziq, and other drugs. Kuvan is frequently prescribed for patients with mild to moderate phenylketonuria as it boosts the activity of the PAH enzyme, providing a non-invasive treatment option for the condition. It is the first oral medication for phenylketonuria that was approved by the FDA and proven to lower phenylalanine levels in patients with certain enzyme functions. Kuvan is frequently combined with dietary control, making it a crucial part of treatment for numerous phenylketonuria patients because of its established efficacy and extensive presence in the market.
Distribution Channel Segment Represents Substantial Market Share
Hospitals and clinics, retail pharmacies, and others together make up the distribution channel segment of the market. Retail pharmacies provide convenient access to specialized dietary items, medications such as Kuvan and Palynziq, low-protein foods, and amino acid supplements. Patients prefer using retail pharmacies to refill medications and supplies to avoid making numerous trips to the hospital.
Phenylketonuria Treatment Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market due to its advanced healthcare system, widespread newborn screening, and strong research and development. Mandatory newborn screening across all states enables early identification and prompt intervention, while market growth is fueled by the availability of innovative therapies. Further, extensive support for phenylketonuria patients is also offered by the United States, which is anticipated to elevate the market value in the forecast period.
EU-4 and the United Kingdom are also poised to have a significant market share supported by robust healthcare systems and government screening initiatives to promote early intervention for genetic conditions. In Oct 2023, POA Pharma launched PKU Easy Microtabs Plus in Germany and the Nordic region. These microtabs are for individuals with phenylketonuria (PKU), marking POA Pharma's entry into the inborn metabolic disease market. The product is a phenylalanine-free protein substitute in micro tablet form, enriched with vitamins and minerals, eliminating the need for separate supplements.Europe's regulations support new phenylketonuria treatments, making them more accessible to patients.
The market in the Japan and India region is rapidly expanding. Japan's extensive screening program and state-of-the-art medical facilities are promoting the expansion of treatment options. On the other side, India's healthcare system is still in the process of development, with the government making substantial efforts for advancements in phenylketonuria diagnosis and treatment.
Leading Players in the Phenylketonuria Treatment Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., headquartered in California, creates groundbreaking medications for rare genetic disorders and illnesses. Their product portfolio includes PALYNZIQ ® (pegvaliase), which is utilized in adults with phenylketonuria (PKU) when alternative approaches such as dietary management prove to be ineffective.
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Homology Medicines, Inc.
Homology Medicines, Inc. is a genetic medicines company focused on rare diseases, aiming to address the root cause of the illness. In July 2023, they shared positive early clinical results for gene editing treatment HMI-103 in adults with classical phenylketonuria (PKU), a severe form of the disease.
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical needs.
Other players in the market are Synology Inc., SOM Innovation Biotech S.A, ERYTECH Pharma S.A, Codexis Inc., Retrophin, Inc., and Abbott Laboratories.
Key Questions Answered in the Phenylketonuria Treatment Market Report
- What was the phenylketonuria treatment market value in 2024?
- What is the phenylketonuria treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on drugs?
- What is the market segmentation based on end users?
- What is the market breakup based on the route of administration?
- What are the major factors aiding the phenylketonuria treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the phenylketonuria treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Phenylketonuria Treatment Market Overview: 8 Major Markets
- 3.1 Phenylketonuria Treatment Market Historical Value (2018-2024)
- 3.2 Phenylketonuria Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Phenylketonuria Treatment: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Phenylketonuria Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Phenylketonuria Treatment Market Landscape: 8 Major Markets*
- 8.1 Phenylketonuria Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Phenylketonuria Treatment Market: Product Landscape
- 8.2.1 Analysis by Drugs
- 8.2.2 Analysis by Route of Administration
- 9 Phenylketonuria Treatment Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Phenylketonuria Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Phenylketonuria Treatment Market Segmentation: 8 Major Markets
- 12.1 Phenylketonuria Treatment Market (2018-2034) by Drugs
- 12.1.1 Market Overview
- 12.1.2 Kuvan
- 12.1.3 CNSA-001
- 12.1.4 SYNB1618
- 12.1.5 Palynziq
- 12.1.6 Others
- 12.2 Phenylketonuria Treatment Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.3 Phenylketonuria Treatment Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals and Clinics
- 12.3.3 Retail Pharmacies
- 12.3.4 Others
- 12.4 Phenylketonuria Treatment Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Phenylketonuria Treatment Market (218-2034)
- 13.1 United States Phenylketonuria Treatment Market Historical Value (2018-2024)
- 13.2 United States Phenylketonuria Treatment Market Forecast Value (2025-2034)
- 13.3 United States Phenylketonuria Treatment Market (2018-2034) by Drugs
- 13.3.1 Market Overview
- 13.3.2 Kuvan
- 13.3.3 CNSA-001
- 13.3.4 SYNB1618
- 13.3.5 Palynziq
- 13.3.6 Others
- 13.4 United States Phenylketonuria Treatment Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.5 United States Phenylketonuria Treatment Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals and Clinics
- 13.5.3 Retail Pharmacies
- 13.5.4 Others
- 14 EU-4 and United Kingdom Phenylketonuria Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Phenylketonuria Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Phenylketonuria Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Phenylketonuria Treatment Market (2018-2034) by Drugs
- 14.3.1 Market Overview
- 14.3.2 Kuvan
- 14.3.3 CNSA-001
- 14.3.4 SYNB1618
- 14.3.5 Palynziq
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Phenylketonuria Treatment Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.5 EU-4 and United Kingdom Phenylketonuria Treatment Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals and Clinics
- 14.5.3 Retail Pharmacies
- 14.5.4 Others
- 15 Japan Phenylketonuria Treatment Market (218-2034)
- 15.1 Japan Phenylketonuria Treatment Market Historical Value (2018-2024)
- 15.2 Japan Phenylketonuria Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Phenylketonuria Treatment Market (2018-2034) by Drugs
- 15.3.1 Market Overview
- 15.3.2 Kuvan
- 15.3.3 CNSA-001
- 15.3.4 SYNB1618
- 15.3.5 Palynziq
- 15.3.6 Others
- 15.4 Japan Phenylketonuria Treatment Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.5 Japan Phenylketonuria Treatment Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals and Clinics
- 15.5.3 Retail Pharmacies
- 15.5.4 Others
- 16 India Phenylketonuria Treatment Market (218-2034)
- 16.1 India Phenylketonuria Treatment Market Historical Value (2018-2024)
- 16.2 India Phenylketonuria Treatment Market Forecast Value (2025-2034)
- 16.3 India Phenylketonuria Treatment Market (2018-2034) by Drugs
- 16.3.1 Market Overview
- 16.3.2 Kuvan
- 16.3.3 CNSA-001
- 16.3.4 SYNB1618
- 16.3.5 Palynziq
- 16.3.6 Others
- 16.4 India Phenylketonuria Treatment Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.5 India Phenylketonuria Treatment Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals and Clinics
- 16.5.3 Retail Pharmacies
- 16.5.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 BioMarin Pharmaceutical Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 PTC Therapeutics, Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Synology Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 SOM Innovation Biotech S.A.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 ERYTECH Pharma S.A.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Codexis, Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 Homology Medicines, Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 Retrophin, Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 Ultragenyx Pharmaceutical Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 23.11 Abbott Laboratories
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Developments
- 23.11.5 Certifications
- 24 Phenylketonuria Treatment Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
